Alaunos Therapeutics, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Alaunos Therapeutics, Inc. (TCRT) reported Increase (Decrease) in Other Noncurrent Liabilities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2025-03-31
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-12-31 was $0.00.
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2023-12-31 was -$500.00K.
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2023-09-30 was $500.00K.
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was $0.00.
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$28.00K, a 200.00% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $28.00K.
- Alaunos Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2021 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month as first filed | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | -$28.00K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $472.00K 10-Q · filed 2024-11-14 | -$28.00K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | -$28.00K 10-Q · filed 2024-08-14 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $28.00K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $28.00K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $28.00K 10-Q · filed 2023-08-14 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | ||||
| 2015-06-30 | $17.00K 10-Q · filed 2016-08-09 | ||||
| 2014-12-31 | -$20.00K 10-K · filed 2017-02-16 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $20.00K 10-K · filed 2016-02-24 | |||
| 2013-09-30 | $20.00K 10-Q · filed 2014-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |